Sphingolipids and Lymphomas: A Double-Edged Sword

Cancers

Luis Mario Villela-Martínez¹  Brady E. Beltrán²  Rosa del Carmen López-Sánchez³  José Ascención Hernández-Hernández³  Alfredo Pherez-Farah³  Rocío Ortiz-López³ 

[1]Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán Rosales 80030, Sinaloa, Mexico

[2]Hospital Edgardo Rebagliati Martins, Lima 15072, Peru

[3]Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Nuevo Leon, Mexico

关键词: lymphoma;    cancer;    lipid metabolism;    lipidomics;    sphingolipids;   

DOI  :  10.3390/cancers14092051

来源: DOAJ

【 摘 要 】

Lymphomas are a highly heterogeneous group of hematological neoplasms. Given their ethiopathogenic complexity, their classification and management can become difficult tasks; therefore, new approaches are continuously being sought. Metabolic reprogramming at the lipid level is a hot topic in cancer research, and sphingolipidomics has gained particular focus in this area due to the bioactive nature of molecules such as sphingoid bases, sphingosine-1-phosphate, ceramides, sphingomyelin, cerebrosides, globosides, and gangliosides. Sphingolipid metabolism has become especially exciting because they are involved in virtually every cellular process through an extremely intricate metabolic web; in fact, no two sphingolipids share the same fate. Unsurprisingly, a disruption at this level is a recurrent mechanism in lymphomagenesis, dissemination, and chemoresistance, which means potential biomarkers and therapeutical targets might be hiding within these pathways. Many comprehensive reviews describing their role in cancer exist, but because most research has been conducted in solid malignancies, evidence in lymphomagenesis is somewhat limited. In this review, we summarize key aspects of sphingolipid biochemistry and discuss their known impact in cancer biology, with a particular focus on lymphomas and possible therapeutical strategies against them.

【 授权许可】

Unknown